Tofacitinib for the Treatment of Pyoderma Gangrenosum
- PMID: 30404036
- DOI: 10.1016/j.cgh.2018.10.047
Tofacitinib for the Treatment of Pyoderma Gangrenosum
Abstract
Pyoderma gangrenosum (PG) is a difficult-to-treat inflammatory skin condition that affects inflammatory bowel disease (IBD) patients. There is no standardized approach for PG treatment.1 We report the results of 3 patients with Crohn's disease (CD) and refractory PG who had failed several therapies with biologics and were started on tofacitinib for severe inflammatory arthritis with resolution of their PG.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
-
Tofacitinib: A Jak of All Trades.Clin Gastroenterol Hepatol. 2019 Jul;17(8):1438-1440. doi: 10.1016/j.cgh.2018.12.044. Epub 2019 Jan 6. Clin Gastroenterol Hepatol. 2019. PMID: 30625401 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical